Sarepta Therapeutics (SRPT) Announces Positive Expression, Biomarker Data from Three-Patient Cohort Dosed in MYO-101 Gene Therapy Trial to Treat LGMD2E, or Beta-Sarcoglycanopathy
Tweet Send to a Friend
In two-month post-treatment muscle biopsies, clinical trial participants showed a mean of 51% beta-sarcoglycan (beta-SG) positive fibers, as measured by ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
